Skip to Content

Adriamycin RDF (doxorubicin) Disease Interactions

There are 4 disease interactions with Adriamycin RDF (doxorubicin):

Major

Antineoplastics (applies to Adriamycin RDF) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
  2. "Product Information. Doxil (doxorubicin liposomal)." Sequis Pharmaceuticals Inc, Menlo Park, CA.
  3. "Product Information. Fludara (fludarabine)." Berlex, Richmond, CA.
  4. Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992): 1396-7
  5. "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
  6. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb, Princeton, NJ.
  7. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  8. "Product Information. Alkeran Tablets (melphalan)." Glaxo Wellcome, Research Triangle Pk, NC.
  9. Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990): 833-4
  10. "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.
  11. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome, Research Triangle Pk, NC.
  12. "Product Information. Hycamtin (topotecan)." SmithKline Beecham, Philadelphia, PA.
  13. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb, Princeton, NJ.
  14. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn, Kalamazoo, MI.
  15. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories, Wayne, NJ.
  16. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.
  17. Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994): 407-8
  18. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb, Princeton, NJ.
  19. "Product Information. Nipent (pentostatin)." Hospira Inc, Lake Forest, IL.
  20. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.
  21. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
  22. "Product Information. DTIC-Dome (dacarbazine)." Bayer, West Haven, CT.
  23. "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation), Eatontown, NJ.
  24. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
  25. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.
  26. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  27. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
  28. Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992): 314-5
  29. "Product Information. Tabloid (thioguanine)." Prasco Laboratories, Cincinnati, OH.
  30. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  31. Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991): 671
View all 31 references
Major

Doxorubicin (applies to Adriamycin RDF) cardiomyopathy

Major Potential Hazard, High plausibility. Applicable conditions: Congestive Heart Failure, History - Myocardial Infarction, Arrhythmias

Myocardial damage, including acute left ventricular failure can occur with doxorubicin. The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20% for cumulative doses ranging from 300 mg/m2 to 500 mg/m2 when doxorubicin is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Additionally, doxorubicin can also cause arrhythmias, including life-threatening events at any point during treatment. Assess LVEF before and regularly during and after treatment with doxorubicin. Doxorubicin is contraindicated in patients with severe myocardial insufficiency and recent myocardial infarction (past 6 months).

References

  1. Haq MM, Legha SS, Choksi J, Hortobagyi GN, Benjamin RS, Ewer M, Ali M "Doxorubicin-induced congestive heart failure in adults." Cancer 56 (1985): 1361-5
  2. Sperber AD, Cantor AA, Biran H, Keynan A "Selective right ventricular dysfunction following doxorubicin therapy." Isr J Med Sci 23 (1987): 896-9
  3. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC "Early anthracycline cardiotoxicity." Am J Med 65 (1978): 823-32
  4. Krivit W "Adriamycin cardiotoxicity amelioration by alpha-tocopherol." Am J Pediatr Hematol Oncol 1 (1979): 151-3
  5. Billingham ME, Bristow MR, Glatstein E, Mason JW, Masek MA, Daniels JR "Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation." Am J Surg Pathol 1 (1977): 17-23
  6. Freter CE, Lee TC, Billingham ME, Chak L, Bristow MR "Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review." Am J Med 80 (1986): 483-5
  7. Lum BL, Svec JM, Torti FM "Doxorubicin: alteration of dose scheduling as a means of reducing cardiotoxicity." Drug Intell Clin Pharm 19 (1985): 259-64
  8. Porembka DT, Lowder JN, Orlowski JP, Bastulli J, Lockrem J "Etiology and management of doxorubicin cardiotoxicity." Crit Care Med 17 (1989): 569-72
  9. Fu LX, Waagstein F, Hjalmarson A "A new insight into adriamycin-induced cardiotoxicity." Int J Cardiol 29 (1990): 15-20
  10. Steinherz L, Steinherz P "Delayed cardiac toxicity from anthracycline therapy." Pediatrician 18 (1991): 49-52
  11. Lee BH, Goodenday LS, Muswick GJ, Yasnoff WA, Leighton RF, Skeel RT "Alterations in left ventricular diastolic function with doxorubicin therapy." J Am Coll Cardiol 9 (1987): 184-8
  12. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA "A clinicopathologic analysis of adriamycin cardiotoxicity." Cancer 32 (1973): 302-14
  13. Lahtinen R, Kuikka J, Nousiainen T, Uusitupa M, Lansimies E "Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study." Eur J Haematol 46 (1991): 301-5
  14. Rinehart JJ, Lewis RP, Balcerzak SP "Adriamycin cardiotoxicity in man." Ann Intern Med 81 (1974): 475-8
  15. McQuillan PJ, Morgan BA, Ramwell J "Adriamycin cardiomyopathy. Fatal outcome of general anaesthesia in a child with adriamycin cardiomyopathy." Anaesthesia 43 (1988): 301-4
  16. Carter SK "Adriamycin-a review." J Natl Cancer Inst 55 (1975): 1265-74
  17. Barendswaard EC, Prpic H, Van der Wall EE, Camps JA, Keizer HJ, Pauwels EK "Right ventricle wall motion abnormalities in patients treated with chemotherapy." Clin Nucl Med 16 (1991): 513-6
  18. Speyer JL, Green MD, Dubin N, Blum RH, Wernz JC, Roses D, Sanger J, Muggia FM "Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast." Am J Med 78 (1985): 555-63
  19. Mortensen SA, Olsen HS, Baandrup U "Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease." Br Heart J 55 (1986): 274-82
  20. Shapira J, Gotfried M, Lishner M, Ravid M "Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation." Cancer 65 (1990): 870-3
  21. Devoy MA, Tomson CR "Fatal cardiac failure after a single dose of doxorubicin in myeloma- associated cardiac amyloid." Postgrad Med J 68 (1992): 69
  22. Benjamin RS, Wiernik PH, Bachur NR "Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule." Cancer 33 (1974): 19-27
  23. Caviale P, McClellan EL "Adriamycin toxicity. Effects in subsequent anesthesia and surgery." J Kans Med Soc 82 (1981): 553,574
View all 23 references
Major

Doxorubicin (applies to Adriamycin RDF) hepatic dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Liver Disease

Doxorubicin is contraindicated in patients with severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL). Doxorubicin is primarily metabolized by the liver and its clearance is reduced in the presence of hepatic dysfunction, increasing the risk for toxicity. Therapy with doxorubicin should be administered cautiously and at a reduced dosage in patients with moderate or mild hepatic function. Close clinical monitoring of hepatic function prior to initiation of doxorubicin therapy is recommended.

References

  1. Aviles A, Herrera J, Ramos E, Ambriz R, Aguirre J, Pizzuto J "Hepatic injury during doxorubicin therapy." Arch Pathol Lab Med 108 (1984): 912-3
  2. Maral RJ, Jouanne M "Toxicology of daunorubicin in animals and man." Cancer Treat Rep 65 Suppl 4 (1981): 9-18
  3. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
Major

Doxorubicin (applies to Adriamycin RDF) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts, Fever, Bleeding

Doxorubicin induces dose-related myelosuppression, primarily affecting leukocytes. Therapy with doxorubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. If the need outweighs the risk, extreme caution should be exercised in administering doxorubicin and the dosage should be reduced. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitory of hematopoietic function is recommended. Doxorubicin is contraindicated in patients with severe persistent drug-induced myelosuppression

References

  1. Bick RL, Fekete LF, Wilson WL "Adriamycin and fibrinolysis." Thromb Res 8 (1976): 467-75
  2. Maral RJ, Jouanne M "Toxicology of daunorubicin in animals and man." Cancer Treat Rep 65 Suppl 4 (1981): 9-18
  3. Doll DC, Weiss RB "Hemolytic anemia associated with antineoplastic agents." Cancer Treat Rep 69 (1985): 777-82
  4. Tan C, Etcubanas E, Wollner N, Rosen G, Gilladoga A, Showel J, Murphy ML, Krakoff IH "Adriamycin--an antitumor antibiotic in the treatment of neoplastic diseases." Cancer 32 (1973): 9-17
  5. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  6. "Product Information. Doxil (doxorubicin liposomal)." Sequis Pharmaceuticals Inc, Menlo Park, CA.
  7. Johnson PJ, Dobbs N, Kalayci C, Aldous MC, Harper P, Metivier EM, Williams R "Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters." Br J Cancer 65 (1992): 751-5
  8. Carter SK "Adriamycin-a review." J Natl Cancer Inst 55 (1975): 1265-74
View all 8 references

Adriamycin RDF (doxorubicin) drug interactions

There are 493 drug interactions with Adriamycin RDF (doxorubicin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.